Janux Therapeutics (JANX) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$0.35
- Estimate
- -$0.30
- Surprise
- -16.8%
- Revenue (period 2026-06-30)
- $10.3M
- Score today
- 5.0/10
Revenue source: xbrl.
How the report landed
Janux Therapeutics (JANX) reported a wider loss than forecast — diluted EPS of -$0.35 against the -$0.30 estimate (a 16.8% shortfall).
Where TrendMatrix's rating stands now
TrendMatrix currently rates JANX Sell at 5.0/10; no pre/post engine snapshot brackets this report.
3 of the last 4 quarters beat the estimate; this quarter's -16.8% surprise compares with a +15.2% four-quarter average. Next scheduled report: 2026-11-05.
What argues against it
- Concentration risk — Pipeline: JANX007 and JANX008
- Quality below floor (1.8 < 4.0)
- Momentum score 3.4/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $16.19
- Price target
- $32.61
- Stop
- $15.56
- Upside to target
- +101.4%
- Reward-to-risk
- 10.1:1
Model outputs from TrendMatrix’s engine as of 2026-09-17 — shown for context, not personalized investment advice.
JANX at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $1.01B
- P/E (fwd)
- -6.3
- 52-week range
- $12.12–$35.34
- Off 52-week high
- 54.2%
- RSI (14)
- 32
- Volume vs avg
- 1.23×
- Score today
- 5.0/10